Literature DB >> 22065721

Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling.

Dirk Spitzer1, Peter O Simon, Hiroyuki Kashiwagi, Jinbin Xu, Chenbo Zeng, Suwanna Vangveravong, Dong Zhou, Katherine Chang, Jonathan E McDunn, John R Hornick, Peter Goedegebuure, Richard S Hotchkiss, Robert H Mach, William G Hawkins.   

Abstract

One major challenge in the development of cancer therapeutics is the selective delivery of the drugs to their cellular targets. In the case of pancreatic cancer, the σ-2 receptor is a unique target that triggers apoptosis upon activation. We have previously developed a series of chemical compounds with high affinity for the σ-2 receptor and showed rapid internalization of the ligands. One particular specific ligand of the σ-2 receptor, SV119, binds to pancreatic cancer cells and induces target cell death in vitro and in vivo. In this study, we characterized the ability of SV119 to selectively deliver other death-inducing cargos to augment the cytotoxic properties of SV119 itself. When conjugated to SV119, small molecules that are known to interfere with intracellular prosurvival pathways retained their ability to induce cell death, the efficiency of which was enhanced by the combinatorial effect of SV119 delivered with its small molecule cargo. Our findings define a simple platform technology to increase the tumor-selective delivery of small molecule therapeutics via σ-2 ligands, permitting chemotherapeutic synergy that can optimize efficacy and patient benefit. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22065721      PMCID: PMC3251632          DOI: 10.1158/0008-5472.CAN-11-1354

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Development of a Tc-99m labeled sigma-2 receptor-specific ligand as a potential breast tumor imaging agent.

Authors:  S R Choi; B Yang; K Plössl; S Chumpradit; S P Wey; P D Acton; K Wheeler; R H Mach; H F Kung
Journal:  Nucl Med Biol       Date:  2001-08       Impact factor: 2.408

2.  New apoptosis drugs face critical test.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2005-04       Impact factor: 54.908

3.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

Authors:  W R Martin; C G Eades; J A Thompson; R E Huppler; P E Gilbert
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

4.  [3H]N-[4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl]-2-methoxy-5-methylbenzamide: a novel sigma-2 receptor probe.

Authors:  Jinbin Xu; Zhude Tu; Lynne A Jones; Suwanna Vangveravong; Kenneth T Wheeler; Robert H Mach
Journal:  Eur J Pharmacol       Date:  2005-11-10       Impact factor: 4.432

Review 5.  Targeting the molecular target of rapamycin (mTOR).

Authors:  Eric K Rowinsky
Journal:  Curr Opin Oncol       Date:  2004-11       Impact factor: 3.645

Review 6.  Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

Authors:  James J Gibbons; Robert T Abraham; Ker Yu
Journal:  Semin Oncol       Date:  2009-12       Impact factor: 4.929

7.  Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice.

Authors:  T H Corbett; B J Roberts; W R Leopold; J C Peckham; L J Wilkoff; D P Griswold; F M Schabel
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

8.  Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer.

Authors:  Bridget N Fahy; Michael G Schlieman; Subbulakshmi Virudachalam; Richard J Bold
Journal:  J Am Coll Surg       Date:  2004-04       Impact factor: 6.113

9.  Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients.

Authors:  Maryann B Flick; David O'Malley; Thomas Rutherford; Sofya Rodov; Marijka Kamsteeg; Xiao-Ying Hao; Peter Schwartz; Barry M Kacinski; Gil Mor
Journal:  J Soc Gynecol Investig       Date:  2004-05

10.  Sigma-2 receptors as a biomarker of proliferation in solid tumours.

Authors:  K T Wheeler; L M Wang; C A Wallen; S R Childers; J M Cline; P C Keng; R H Mach
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

View more
  20 in total

1.  Potential Molecular Mechanisms on the Role of the Sigma-1 Receptor in the Action of Cocaine and Methamphetamine.

Authors:  Yuko Yasui; Tsung-Ping Su
Journal:  J Drug Alcohol Res       Date:  2016-02-20

2.  Sigma receptors [σRs]: biology in normal and diseased states.

Authors:  Colin G Rousseaux; Stephanie F Greene
Journal:  J Recept Signal Transduct Res       Date:  2015-06-09       Impact factor: 2.092

Review 3.  Principles in the design of ligand-targeted cancer therapeutics and imaging agents.

Authors:  Madduri Srinivasarao; Chris V Galliford; Philip S Low
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

Review 4.  Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands.

Authors:  John R Hornick; Dirk Spitzer; Peter Goedegebuure; Robert H Mach; William G Hawkins
Journal:  Surgery       Date:  2012-07-03       Impact factor: 3.982

5.  Dependence of glucose transport on autophagy and GAPDH activity.

Authors:  Rolf J Craven; Hilaree N Frazier; Olivier Thibault
Journal:  Brain Res       Date:  2021-12-02       Impact factor: 3.252

6.  SW43-DOX ± loading onto drug-eluting bead, a potential new targeted drug delivery platform for systemic and locoregional cancer treatment - An in vitro evaluation.

Authors:  Johannes M Ludwig; Yongkang Gai; Lingyi Sun; Guangya Xiang; Dexing Zeng; Hyun S Kim
Journal:  Mol Oncol       Date:  2016-05-21       Impact factor: 6.603

Review 7.  The σ2 receptor: a novel protein for the imaging and treatment of cancer.

Authors:  Robert H Mach; Chenbo Zeng; William G Hawkins
Journal:  J Med Chem       Date:  2013-06-18       Impact factor: 7.446

8.  Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134.

Authors:  Yassar M Hashim; Dirk Spitzer; Suwanna Vangveravong; Mary C Hornick; Gunjal Garg; John R Hornick; Peter Goedegebuure; Robert H Mach; William G Hawkins
Journal:  Mol Oncol       Date:  2014-03-26       Impact factor: 6.603

9.  Characterization of spherulites as a lipidic carrier for low and high molecular weight agents.

Authors:  Peng Zhang; Yixian Huang; Alexander M Makhov; Xiang Gao; Peijun Zhang; Song Li
Journal:  Pharm Res       Date:  2013-04-12       Impact factor: 4.200

10.  Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting.

Authors:  Federico Perche; Vladimir P Torchilin
Journal:  J Drug Deliv       Date:  2013-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.